Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

CDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Cision, a global leader in media intelligence and communications solutions, in partnership with PRWeek, today announced the ...

Zebra Technologies Corporation , a global leader in digitizing and automating frontline workflows, today announced that the company will present at the Morgan Stanley Technology, Media & Telecom ...

Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this disease space alongside Avidity Biosciences, Lupin and AMO Pharma. Last month, ...